FLT3-ITD Targeted Therapy in Fit AML Patients

Inclusion Criteria: * Newly diagnosed AML cytopathologically confirmed according to the 5th WHO classification * Age between 18 and 75 years * FLT3-ITD mutation as per local IVDR-compliant testing. Positivity is defined as a FLT3-ITD / FLT3-wild type (WT) ratio of ≥ 0.05 (5%)) * Eligibility for standard induction chemotherapy * ECOG PS ≤ 2 * WBC ≤25 x 10\^9/L (hydroxyurea, leukapheresis or cytarabine in specific clinical circumstances, are allowed to meet this criterion. Please refer to Section 4.1.1 - Inclusion Criteria). * Adequate hepatic function (as indicated by total serum bilirubin level ≤2.5 x the institutional upper limit of normal range (UNL), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the investigator; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤3 x UNL) * Adequate renal function as defined by an eGFR ≥ 30 mL/min according to the 2021 CKD-EPI equation Main Exclusion Criteria: * Acute promyelocytic leukemia (APL) * BCR-ABL positive leukemia or Ph1-positive chronic myeloid leukemia * History of myeloproliferative neoplasm (MPN), including myelofibrosis, essential thrombocythemia, polycythemia vera * Active central nervous system involvement by AML * Active, uncontrolled infection (viral, bacterial or fungal): an infection controlled with an approved or closely monitored antibiotic/antifungal treatment is allowed. * HIV, HBV or HCV active infection * Grade \>3 CTCAE (v. 6) clinically relevant (…